Table 5. Scenario analyses compared with base findings.

			HIV Vaccine	Dual vaccine	PrEP	VMMC
Discount rate	0%	Net cost	4.81	14.28	13.06	12.54
		QALYs gained	447.38	84.42	2 236.88	370.65
		ICER	93.05	5.91	171.22	29.56
	6%	Net cost	4.80	14.31	13.03	12.51
		QALYs gained	446.76	107.58	2 254.96	385.58
		ICER	93.10	7.52	173.05	30.82
Cost	High	Net cost	4.80	14.30	13.04
		QALYs gained	532.55	193.14	2 247.83	n/a
		ICER	110.92	13.50	172.41
	Low	Net cost	4.80	14.30	13.04
		QALYs gained	399.66	51.73	1 723.95	n/a
		ICER	83.24	3.62	132.23
	Very low	Net cost	4.80	14.30	13.04
		QALYs gained	373.12	23.48	1 400.79	n/a
		ICER	77.71	1.64	107.44
Effectiveness	High	Net cost	4.69	15.03	13.04
		QALYs gained	426.61	99.47	2 253.37	n/a
		ICER	90.97	6.62	172.83
	Low	Net cost	4.92	13.61	10.19
		QALYs gained	464.96	101.02	1 869.09	n/a
		ICER	94.58	7.42	183.5
Coverage	High	Net cost	5.60	16.68	15.21	14.60
		QALYs gained	486.72	84.23	2 557.83	371.64
		ICER	86.89	5.05	168.16	25.45
	Low	Net cost	2.40	7.15	6.52	6.26
		QALYs gained	321.49	148.99	1 339.99	403.06
		ICER	133.92	20.84	205.55	64.41

One way sensitivity analysis was done to systematically examine the impact of selected variables in the analysis by varying it across a plausible range of values with other variables remaining at their baseline level.

ART: Antiretroviral Therapy; HIV: Human Immunodeficiency Virus; HPV: Human Papillomavirus; Dual Vaccine: HIV and HPV Vaccinations; VMMC: Voluntary Male Medical Circumcision; Prep: Pre-Exposure Prophylaxis